PLEXXIKON ENGINEERING DRUGS FOR PERSONALIZED MEDICINE

DEAD

Serial Number

87502892

Owner

Plexxikon Inc.

Attorney

Harold Milstein

Filing Date

Jun 23, 2017

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

PLEXXIKON ENGINEERING DRUGS FOR PERSONALIZED MEDICINE Trademark

Serial Number: 87502892

PLEXXIKON ENGINEERING DRUGS FOR PERSONALIZED MEDICINE is a trademark filed by Plexxikon Inc. on June 23, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

Plexxikon Inc. (8 trademarks)

91 Bolivar Drive
Berkeley, CA 94710

Entity Type: 03

Legal Representation

Attorney of Record

Harold Milstein

1,016 trademarks filed View all →

Trademark Details

Filing Date

June 23, 2017

Registration Date

Not Registered

Published for Opposition

November 14, 2017

Goods & Services

Pharmaceutical preparations for the treatment of cancer, diabetes, and central nervous system, autoimmune, bone, metabolic, and blood disorders

Product development research, product development, and product development consultation regarding pharmaceutical, biological and biotechnological products; Pharmaceutical research and development services; medical research and development services in the field of treatments for cancer, diabetes, and central nervous system, autoimmune, bone, metabolic, and blood disorders

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Feb 10, 2020 MAB6

ABANDONMENT - NO USE STATEMENT FILED

Feb 10, 2020 ABN6

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jul 3, 2019 EXRA

SOU EXTENSION 3 GRANTED

Jul 1, 2019 EX3G

SOU EXTENSION 3 FILED

Jul 1, 2019 EXT3

SOU TEAS EXTENSION RECEIVED

Jul 1, 2019 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jan 8, 2019 EXRA

SOU EXTENSION 2 GRANTED

Jan 4, 2019 EX2G

SOU EXTENSION 2 FILED

Jan 4, 2019 EXT2

SOU TEAS EXTENSION RECEIVED

Jan 4, 2019 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Jul 10, 2018 EXRA

SOU EXTENSION 1 GRANTED

Jul 6, 2018 EX1G

SOU EXTENSION 1 FILED

Jul 6, 2018 EXT1

SOU TEAS EXTENSION RECEIVED

Jul 6, 2018 EEXT

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Jan 9, 2018 NOAM

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Nov 14, 2017 NPUB

PUBLISHED FOR OPPOSITION

Nov 14, 2017 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Oct 25, 2017 NONP

ASSIGNED TO LIE

Oct 9, 2017 ALIE

APPROVED FOR PUB - PRINCIPAL REGISTER

Sep 22, 2017 CNSA

EXAMINER'S AMENDMENT ENTERED

Sep 22, 2017 XAEC

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Sep 22, 2017 GNEN

EXAMINERS AMENDMENT E-MAILED

Sep 22, 2017 GNEA

EXAMINERS AMENDMENT -WRITTEN

Sep 22, 2017 CNEA

ASSIGNED TO EXAMINER

Sep 21, 2017 DOCK

NOTICE OF DESIGN SEARCH CODE E-MAILED

Jul 1, 2017 MDSC

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Jun 30, 2017 NWOS

NEW APPLICATION ENTERED

Jun 27, 2017 NWAP

Related Trademarks

More from this Owner

PLEXXIKON SCAFFOLD-BASED DRUG DISCOVERY

PLEXXIKON ENGINEERING DRUGS FOR PERSONALIZED MEDICINE

PLEXXIKON SCAFFOLD-BASED DRUG DISCOVERY

More in Same Class

MUSCLE MOOSE

IOVANCE BIOTHERAPEUTICS ADVANCING IMMUNO-ONCOLOGY

TETRACUMIN

GP GOODNESS

LACTOFRIEND

ADAGE